Asia Pac ECM and Index Rebal, DZT Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

InSilico Medicine (英矽智能) IPO: AI Assets as Upside

Insilico Medicine Pre-IPO - An Emerging AI-Enabled Drug Discovery Platform

Pre-IPO InSilico Medicine (PHIP Updates) - Some Points Worth the Attention

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

Insilico Medicine / Equity Capital Markets

<ul>
<li>InSilico Medicine raised HKD 2025m (USD 261m) from its global offering and will list on the Hong Kong Stock Exchange on Tuesday December 30, 2025.</li>
<li>In our previous note, we looked at the company's fundamentals, and an assessment of the value of its pipelines.</li>
<li>In this note, we provide an update for the IPO before trading debut.</li>
</ul>


InSilico Medicine raised HKD 2025m (USD 261m) from its global offering and will list on the Hong Kong Stock Exchange on Tuesday December 30, 2025.
In our previous note, we looked at the company's fundamentals, and an assessment of the value of its pipelines.
In this note, we provide an update for the IPO before trading debut.


InSilico Medicine (英矽智能) IPO 거래